DDIS-22. DRUG SCREEN IN PATIENT-DERIVED IDHMUT GLIOMA STEM CELLS IDENTIFIES SEVERAL FDA-APPROVED ANTINEOPLASTIC AGENTS

OBJECTIVE: The discovery of the Isocitrate Dehydrogenase (IDH) mutation in glioma has led to a paradigm shift on how we see glioma biology. While it is clear, that IDH mutated (IDHmut) and wildtype (IDHwt) tumors have to be viewed as separate entities, the underlying biological differences are still...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Dao Trong, Philip, Pusch, Stefan, Unterberg, Andreas, Herold-Mende, Christel, Warta, Rolf
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2019
Assuntos:
Drug Discovery
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847371/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.273
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares